Shenzhen Institute for Innovation and Translational Medicine
1 clinical trials · Sponsor
◉ Watch Shenzhen Institute for Innovation and Translational Medicine
| Record | Firm | Date |
|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies (NCT03076437) | Shenzhen Institute for Innovation and Translational Medicine | 2016-01-15 |
Track Shenzhen Institute for Innovation and Translational Medicine automatically
Every clearance here is in the API, with alerts when new ones post.